Feasibility assessment for outpatient CRS monitoring across care settings
CAR-T and T-cell engager (TCE) therapies can be delivered safely outside the hospital.
Right now, the barrier is not technology; it is the care model. Sites need workflows, staffing, and infrastructure built for outpatient monitoring before they can deliver these therapies safely outside the hospital.
The site readiness checklist brings together stakeholder input and the clinical, operational, and economic considerations for what that takes, organized into resources below.
A stakeholder-informed assessment of the clinical, operational, technological, and economic requirements for cytokine release syndrome (CRS) monitoring in outpatient settings following CAR-T and T-cell engager therapies
THE CASE FOR OUTPATIENT CRS MONITORING | A distillation of the report’s value case and key evidence, built to lift straight into your own presentations when you’re making the case to leadership, payers, or partners.
Monitoring CRS outside the hospital only produces useful data if every site defines and grades an event the same way. The adjudication framework provides that shared standard by providing you with a decision flowchart and supporting guide for identifying, documenting, and grading a complete CRS event.